

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/584,445-Conf. #4148
		Filing Date	June 22, 2006
		First Named Inventor	Elie LEVERD
		Art Unit	1614
		Examiner Name	T. P. Thomas
Sheet	1	of	2
		Attorney Docket Number	3493-0170PUS1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-4,966,903	10-30-1990	Leverd et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
	BA	GB-2 125 292 A	03-07-1984		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	¹
	CA	Cyberbotanica: "Pharmacology of vinblastine, vincristine, vindesine and vinorelbine from http://biotech.icmb.utexas.edu/botany/www.html	
	CB	Product label from http://www.accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN=vincristine	
	CC	Eldisine® Injection from RxMed: Pharmaceutical information-Eldisine (www.rxmed.com/b_main/b2_pharmaceutical/b2_1_monographs/)	
	CD	Vendrig et al., "Degradation kinetics of vincristine sulphate and vindesine sulphate in aqueous solution", International Journal of Pharmaceutics, 50 (1989), pp. 189-196	
	CE	Jaquesy et al., "Fluorination in superacids: a novel access to biologically active compounds", Journal of Fluorine Chemistry 114 (2002), pp. 139-141	
	CF	Fahy et al., "Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives", J. Am. Chem. Soc. 1997, 119, pp. 8576-8577	
	CG	Abstract No. 1329 of Bichat et al. in Proceedings of the American Association of Cancer Research, vol. 43, March 2002, "Antitumor activity study of vinorelbine against human PC-3 prostate tumor xenografted in nude rats".	
	CH	Abstract No. 1330 of Sweet et al. in Proceedings of the American Association of Cancer Research, vol. 43, March 2002, "Increased efficacy of liposomal vincristine compared to conventional vincristine in ectopic and orthotopic tumor models".	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/584,445-Conf. #4148		
		Filing Date	June 22, 2006		
		First Named Inventor	Elie LEVERD		
		Art Unit	1614		
		Examiner Name	T. P. Thomas		
Sheet	2	of	2	Attorney Docket Number	3493-0170PUS1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CI	Abstract No. 1331 of H-H Fiebig et al. in Proceedings of the American Association of Cancer Research, vol. 43, March 2002 "Anticancer activity of vinflunine, a novel fluorinated vinca alkaloid in human pancreas, renal and non-small cell (NSCL) lung tumor xenografts".	
	CJ	Abstract No. 1332 of Kruczynski et al. in Proceedings of the American Association Cancer Research, vol. 43, March 2002, "Significant antiangiogenic activity and marked inhibition of growth of an orthotopic colon cancer model and colon cancer liver metastases by vinflunine, the most recent vinca alkaloid in clinical development".	
	CK	Abstract No. 1333 of Kruczynski et al. in Proceedings of the American Association Cancer Research, vol. 43, March 2002, "Markedly augmented in vivo experimental antitumor activity with vinflunine, the most recent Vinca alkaloid to show activity in Phase I clinical trials, when combined with DNA damaging anticancer agents."	
	CL	Abstract No. 1334 of Okouneva et al. in Proceedings of the American Association Cancer Research, vol. 43, March 2002, "How do the new Vinca alkaloids vinflunine and vinorelbine block mitosis? Effects on centromere movements in living mitotic U20s cells".	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.